On Tuesday, Invesco Ltd. (NYSE:IVZ)’s shares inclined 0.24% to $37.49.
Invesco Ltd. (IVZ) declared portfolio administration changes for the following Invesco closed-end municipal funds (the “Funds”):
The following individuals are jointly and primarily responsible for the day-to-day administration of each Fund’s portfolio:
William Black, Portfolio Manager, who has been associated with Invesco and/or its associates since 2010. From 1998 to 2010, Mr. Black was associated with Van Kampen Asset Administration and/or its associates in an investment administration capacity.
Thomas Byron, Portfolio Manager, who has been associated with Invesco and/or its associates since 2010. From 1981 to 2010, Mr. Byron was associated with Van Kampen Asset Administration and/or its associates in an investment administration capacity.
Mark Paris, Portfolio Manager, who has been associated with Invesco and/or its associates since 2010. From 2002 to 2010, Mr. Paris was associated with Van Kampen Asset Administration and/or its associates in an investment administration capacity.
James Phillips, Portfolio Manager, who has been associated with Invesco and/or its associates since 2010. From 1991 to 2010, Mr. Phillips was associated with Van Kampen Asset Administration and/or its associates in an investment administration capacity.
Robert Stryker, Portfolio Manager, who has been associated with Invesco and/or its associates since 2010. From 1994 to 2010, Mr. Stryker was associated with Van Kampen Asset Administration and/or its associates in an investment administration capacity.
Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced and fixed income portfolios.
DiamondRock Hospitality Company (NYSE:DRH)’s shares gained 0.08% to $12.81.
DiamondRock Hospitality Company (DRH) declared that its Board of Directors declared a quarterly dividend of $0.125 per share to stockholders of record as of June 30, 2015. The dividend will be paid on July 14, 2015.
DiamondRock Hospitality Company, a lodging focused real estate company, owns premium hotels and resorts in North America. The company operates its hotels under the Hilton, Marriott, and Westin brand names in New York, Los Angeles, Chicago, Boston, and Atlanta; and in destination resort locations, such as the United States Virgin Islands and Colorado.
At the end of Tuesday’s trade, Xilinx, Inc. (NASDAQ:XLNX)‘s shares surged 0.43% to $44.16.
Xilinx, Inc. (XLNX) declared that it was presented the winner of the Outstanding Components Vendor category in the 2015 Leading Lights Awards, organized by Light Reading publication. Xilinx was chosen from a field that comprised of six other entrants at the Leading Lights awards dinner in Chicago on Monday, June 8, coinciding with the Big Telecom Event. The Outstanding Components Vendor category recognized the vendor that stands out from its competitors, innovates constantly, assists set the industry trends, makes investors proud, and makes employees happy.
Xilinx, Inc. designs and develops programmable devices and associated technologies worldwide. Its programmable devices comprise integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; software design tools to program the PLDs; targeted reference designs; printed circuit boards; and intellectual property (IP), which comprises of Xilinx and various third-party verification and IP cores.
Asterias Biotherapeutics Inc (NYSEMKT:AST), ended its Tuesday’s trading session with 24.32% gain, and closed at $4.60.
Asterias Biotherapeutics, Inc. (AST), a biotechnology company focused on the emerging field of regenerative medicine, recently declared that the first patient was successfully dosed at the Atlanta-based Shepherd Center in a Phase 1/2a clinical trial evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). The Phase 1/2a trial is part of the planned registration program for AST-OPC1, with neurologically complete cervical SCI as the first targeted indication.
The open-label, single-arm study, which will be conducted at a total of up to eight centers in the United States, will test three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in 13 patients with sub-acute, C-5 to C-7, neurologically complete cervical SCI. These individuals have essentially lost all sensation and movement below their injury site with severe paralysis of the upper and lower limbs. AST-OPC1 will be administered 14 to 30 days post-injury. Patients will be followed by neurological exams and imaging methods to assess the safety and activity of the product. Additional information on the Phase 1/2a study, counting trial sites, can be found at www.clinicaltrials.gov, using Identifier NCT02302157.
Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. It is developing pluripotent stem-cell therapeutic products in the areas of neurology and oncology. The company’s product candidates comprise AST-OPC1, which is in Phase I/IIa clinical trial for the treatment of spinal cord injury, multiple sclerosis, and stroke; and AST-VAC2, the allogeneic dendritic cells loaded with telomerase antigen for the treatment of non-small cell lung cancer, in addition to multiple cancer types, antigens, and infectious diseases. It is also developing AST-VAC1 for the treatment of prostate cancer and acute myelogenous leukemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
